Press Releases
Press releases
Filter by year
Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting
Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting
Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium
Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024
Biora Therapeutics Achieves ISO 13485 Certification
Biora Therapeutics Announces Positive Nasdaq Listing Decision
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Biora Therapeutics Announces Funding Agreement with Existing Investors
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
Biora Therapeutics Provides Outlook for 2024
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
Biora Therapeutics Submits Updated IND Application for BT-600
Biora Therapeutics to Submit Updated IND Application for BT-600
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure
Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
Biora Therapeutics Progresses its BioJet™ Systemic Oral Delivery Platform
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform
Biora Therapeutics to Participate in Canaccord Genuity 43rd Annual Growth Conference
Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform
Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update
Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets
Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions
Biora Therapeutics Announces Closing of $8 Million Registered Direct Offering of Common Stock and Warrants Priced At-the-Market Under Nasdaq Rules
Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update
Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer
Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist
Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform
Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress
Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023
Biora Therapeutics Announces Reverse Stock Split
Biora Therapeutics Announces Two Poster Presentations at the Crohn’s & Colitis Congress
Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Biora Therapeutics Announces $9.75 Million Direct Offering
Biora Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update
Biora Therapeutics Announces Sale of Cell-Free DNA Patent Rights
Biora Therapeutics Shares Data from Device Performance Study in Ulcerative Colitis Patients
Biora Therapeutics Shares Five Posters Presented at American College of Gastroenterology Annual Scientific Meeting 2022
Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference
Biora Therapeutics to Participate in 12th Annual Partnership Opportunities in Drug Delivery Conference
Biora Therapeutics Announces Issuance of Key Patent for Oral Delivery of GLP-1 Receptor Agonists
Biora Therapeutics Appoints Dr. Bruce Sands as Chair of its Clinical Advisory Board
Biora Therapeutics to Participate in Upcoming H.C. Wainwright Investment Conference
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform
Biora Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update
Biora Therapeutics Announces Five Abstracts Accepted at American College of Gastroenterology Annual Scientific Meeting 2022
Biora Therapeutics to Participate in Upcoming BTIG Investment Conference
Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at Controlled Release Society 2022
Biora Therapeutics Announces Successful Completion of Second Device Performance Study in Human Subjects for its Targeted Therapeutics Platform
Biora Therapeutics Announces Presentation at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference
Biora Therapeutics Shares Presentation of Patient Data Establishing Correlation Between Drug Levels in Colon and Patient Outcomes in Ulcerative Colitis
Biora Therapeutics Shares Data Presented at Digestive Disease Week 2022
Biora Therapeutics Announces New Patents for Targeted Therapeutics Platform
Biora Therapeutics to Participate in Upcoming H.C. Wainwright Global Investment Conference
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
Page 1 of 1